EP1185270A4 - Interleukin-8 rezeptor-antogonisten - Google Patents

Interleukin-8 rezeptor-antogonisten

Info

Publication number
EP1185270A4
EP1185270A4 EP00942934A EP00942934A EP1185270A4 EP 1185270 A4 EP1185270 A4 EP 1185270A4 EP 00942934 A EP00942934 A EP 00942934A EP 00942934 A EP00942934 A EP 00942934A EP 1185270 A4 EP1185270 A4 EP 1185270A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00942934A
Other languages
English (en)
French (fr)
Other versions
EP1185270A1 (de
Inventor
Deborah L Bryan
John G Gleason
Katherine L Widdowson
Gregory M Benson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1185270A1 publication Critical patent/EP1185270A1/de
Publication of EP1185270A4 publication Critical patent/EP1185270A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP00942934A 1999-06-16 2000-06-16 Interleukin-8 rezeptor-antogonisten Withdrawn EP1185270A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967799P 1999-06-16 1999-06-16
US139677P 1999-06-16
PCT/US2000/016814 WO2000076517A1 (en) 1999-06-16 2000-06-16 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
EP1185270A1 EP1185270A1 (de) 2002-03-13
EP1185270A4 true EP1185270A4 (de) 2004-02-11

Family

ID=22487800

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00942934A Withdrawn EP1185270A4 (de) 1999-06-16 2000-06-16 Interleukin-8 rezeptor-antogonisten

Country Status (9)

Country Link
EP (1) EP1185270A4 (de)
JP (1) JP2003501472A (de)
AU (1) AU5748300A (de)
CO (1) CO5190712A1 (de)
EC (1) ECSP003527A (de)
HK (1) HK1044475A1 (de)
PE (1) PE20010321A1 (de)
UY (1) UY26207A1 (de)
WO (1) WO2000076517A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity
WO2005113534A2 (en) 2004-05-12 2005-12-01 Schering Corporation Cxcr1 and cxcr2 chemokine antagonists
EP3355876A2 (de) * 2015-09-30 2018-08-08 Instituto de Medicina Molecular Verfahren zur abschwächung der virulenz von parasiten

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006399A1 (en) * 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2928485A1 (de) * 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
ATE98223T1 (de) * 1988-03-30 1993-12-15 Warner Lambert Co N-(((2,6-disubstituierte)phenyl>n'- arylalkyl> harnstoffe als antihypercholesterolemische und antiatherosclerotische mittel.
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006399A1 (en) * 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARADA AKIHISA ET AL: "Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases", MOLECULAR MEDICINE TODAY, vol. 2, no. 11, 1996, pages 482 - 489, XP002264509, ISSN: 1357-4310 *
See also references of WO0076517A1 *

Also Published As

Publication number Publication date
JP2003501472A (ja) 2003-01-14
HK1044475A1 (zh) 2002-10-25
EP1185270A1 (de) 2002-03-13
AU5748300A (en) 2001-01-02
ECSP003527A (es) 2002-01-25
CO5190712A1 (es) 2002-08-29
UY26207A1 (es) 2000-12-29
PE20010321A1 (es) 2001-05-18
WO2000076517A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
EP1284956A4 (de) Il-8 receptor antagonisten
PL352232A1 (en) Il-8 receptor antagonists
DZ3309A1 (en) Il-8 receptor antagonists
AU4560601A (en) Il-8 receptor antagonists
IL145762A0 (en) Il-8 receptor antagonists
IL146046A0 (en) Il-8 receptor antagonists
EP1274415A4 (de) Il-8 rezeptorantagonisten
AP2002002599A0 (en) Il-8 receptor antagonists
EP1265905A4 (de) Il-2 receptor antagonisten
IL146053A0 (en) Il-8 receptor antagonists
EP1274413A4 (de) Il-8 rezeptorantagonisten
EP1263427A4 (de) Il-8 rezeptor antagonisten
EP1274428A4 (de) Il-8-rezeptorantagonisten
EP1047424A4 (de) Il-8 rezeptor antagonisten
EP1039903A4 (de) Il-8 rezeptor antagonisten
EP1194143A4 (de) Il-8 rezeptor-antagonisten
EP1261329A4 (de) Il-8-rezeptor-antagonisten
AU5748300A (en) Il-8 receptor antagonists
PL352218A1 (en) Il-8 receptor antagonists
IL146515A0 (en) Il-8 receptor antagonists
PL346178A1 (en) Il-8 receptor antagonists
EP1265603A4 (de) Il-9 receptor-antagonisten
EP1237548A4 (de) Il-8 rezeptor antagonisten
ZA985813B (en) IL-8 receptor antagonists
ZA985975B (en) IL-8 receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/155 B

Ipc: 7A 61K 31/44 A

A4 Supplementary search report drawn up and despatched

Effective date: 20031230

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040317

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1044475

Country of ref document: HK